Navigation Links
Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
Date:11/27/2011

LAGUNA NIGUEL, Calif., Nov. 28, 2011 /PRNewswire/ --  Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the initiation of patient enrollment in the second of two pivotal studies in the Company's OBI-1 Accur8 clinical trial program.  In the newly initiated clinical study, OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, will be evaluated for the treatment of individuals with congenital hemophilia A who have developed inhibitory antibodies (inhibitors) against their human FVIII replacement therapy.  In achieving this milestone, Inspiration has received a $25 million milestone payment from the Ipsen Group (Euronext: IPN; ADR: IPSEY), under a partnership agreement signed with Ipsen in January 2010.  In return, Inspiration has issued Ipsen a convertible note, bringing Ipsen's fully diluted ownership position in Inspiration to 40.7%.

The OBI-1 pivotal clinical study is a prospective, non-randomized, open-label study evaluating the efficacy of OBI-1 for the treatment of serious bleeding episodes, including episodes that are a threat to a patient's life or vital organs. 

Dr. Johnny Mahlangu, MD, Director of the Adult Hemophilia Comprehensive Care Unit at Johannesburg Hospital, and President of the South African Society of Hematology, commented, "There remains a significant unmet medical need when it comes to treating individuals with hemophilia A who have developed inhibitors.  Current therapies do not reach the same level of efficacy as replacement therapy for non-inhibitor patients, leading to potential joint complications, increased risk of bleeding, pain and impact on the patient's quality of life.  Unlike available bypassing agents, OBI-1 facilitates the intrinsic hemostatic pathway, and therefore may allow clinicians to correlate activity and efficacy with FVIII levels (a surrogate for efficacy), enabling them to guide dosing and better predict treatment outcomes.  We are
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
9. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
10. Inspiration Biopharmaceuticals Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia at 23rd ISTH Congress
11. Heskas 2011 "Inspiration in Action" Contest Begins: Support the Veterinary Profession and Help Animals in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company (NYSE: ... previously announced cash tender offer for up to $1.6 billion ... Holders of notes who tendered, and did not ... New York City time, on May 27, ... purchase by Lilly, are eligible to receive the total consideration. ...
(Date:5/28/2015)... May 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... second quarter and three and six months ended March 31, ... and in accordance with International Financial Reporting Standards ("IFRS"). ... net loss of $5.9 million ($0.35 per common share) for ... a net loss of $0.4 million ($0.03 per common share) ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... 2011 Misonix, Inc. (NASDAQ: MSON ... and markets innovative therapeutic ultrasonic products worldwide for ... surgery and other surgical and medical applications, announced ... Symposium on Advances in Skin and Wound Care ...
... Every year thousands of children are hospitalized — and ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share stolen prescription ... pills that look like candy. In this ... can prevent harm by locking your medicine up. ...
Cached Medicine Technology:Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 2Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 3
(Date:5/29/2015)... 29, 2015 The Global Allopurinol ... study on the current state of the Allopurinol ... key statistics on the state of the industry ... direction for companies and individuals interested in the ... the industry including definitions, classifications, applications and industry ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Designed with ... teamed up to create an all new, exclusive line ... a formulated with the latest and greatest, high impact, ... proven to be effective. The 24/7 Series can be ... cross-fitters and even the casual fitness enthusiasts. There are ...
(Date:5/29/2015)... May 29, 2015 Javlin continues to ... U.S. headquarters and a larger team, with the intention ... CloverETL's market share in the U.S. and Canada. , ... Group, achieved significant growth in 2014 with its strongest ... premier data integration platform, CloverETL. To accelerate further progress ...
(Date:5/29/2015)... 2015 This is a professional ... the Naproxen industry.The report provides a basic overview ... industry chain structure. The Naproxen market ... development trends, competitive landscape analysis, and key regions ... well as manufacturing processes and cost structures are ...
(Date:5/29/2015)... Michigan (PRWEB) May 29, 2015 Vulvodynia ... and can cause significant physical, sexual, and psychological distress. ... altering disorder of Vulvodynia. The actual diagnosis is often ... in Endometriosis, they realize that this problem can be ... experiencing any of these symptoms, they need to schedule ...
Breaking Medicine News(10 mins):Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... ReauthorizationWASHINGTON, Jan. 14 The following fact sheet was ... the House: Divided We Fail Partnership (AARP, Business Roundtable, ... "On behalf of Divided We Fail, we urge you ... Children,s Health Insurance Program (SCHIP). Our nation has a ...
... journal report:Study highlights:-- Cholesterol-lowering drug adherence drops with ... of going for 90 straight days without medication ... all co-payment group and twice as high in ... to the exempt group (received prescriptions without a ...
... Utilize MICROSPONGE(R) Delivery SystemCARLSBAD, Calif., Jan. 14 ... Micro Wash, the only prescription benzoyl ... delivery system, for the treatment of mild ... Wash contains 7% benzoyl peroxide.(Photo: http://www.newscom.com/cgi-bin/prnh/20090114/LA58962 ...
... Rehab MarketHOUSTON, Jan. 14 Anne Kieschnik, a complex ... joined Alliance Seating & Mobility (ASM), one ... Kieschnik is an Assistive Technology Professional (ATP) ... for ASM ( www.alliance-seating.com ) and is responsible for ...
... access journal reportStudy highlights:, , ... odds of having cardiovascular disease within 10 years may not be ... Most adults 50 years and younger have a low 10-year risk ... disease. , Researchers suggest using ...
... blood-sucking critters, resistance to insecticides increasing in urban areas , , ... insecticides appears to be why bed bugs are making a ... , Bed bugs in New York City, where infestations have ... mutations that weaken the effect of the pyrethroid toxins, such ...
Cached Medicine News:Health News:Health Care For 11 Million Children 2Health News:Health Care For 11 Million Children 3Health News:Health Care For 11 Million Children 4Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 2Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 3Health News:Co-Payment Increases Result in Gaps in Veterans' Prescription Usage 4Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 2Health News:SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne 3Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 2Health News:Veteran Rehab Specialist, Anne Kieschnik, Joins Fast-Growing Alliance Seating & Mobility In Texas 3Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 2Health News:Half of Adults 50 and Younger With Low 10-Year Risk of CVD Have High Lifetime Risk 3Health News:Bed Bugs, Nearly Eradicated, Make a Comeback 2
... vascular tests for assessing peripheral vascular disease. With the Portable ABI Kit, you get the basic equipment ... ... ... The ankle-arm pressure index (also known as the Ankle/Brachial ...
... Clinitek Microalbumin Strips provide albumin, creatinine ... The Clinitek Microalbumin product is useful to ... or hypertension in order to detect early ... elevation of the urinary albumin excretion rate, ...
... today's busy physician's office environment, ... contribute to timing errors and ... strips are read visually. Studies ... is performed with an instrument, ...
... Ultra device consists of a non-compliant balloon ... mounted longitudinally on its outer surface. When ... the atherotomes score the plaque, creating initiation ... to as Atherotomy, allows dilatation of the ...
Medicine Products: